

Stefan Ståhl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11828929/publications.pdf>

Version: 2024-02-01

140
papers

8,481
citations

47006

47
h-index

49909

87
g-index

141
all docs

141
docs citations

141
times ranked

6214
citing authors

#	ARTICLE	IF	CITATIONS
1	Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti- $\text{A}\beta^2$ -Affibodies. <i>Pharmaceutical Research</i> , 2022, , 1.	3.5	1
2	Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. <i>Biomedicines</i> , 2022, 10, 1293.	3.2	2
3	HER3 PET Imaging: ^{68}Ga -Labeled Affibody Molecules Provide Superior HER3 Contrast to ^{89}Zr -Labeled Antibody and Antibody-Fragment-Based Tracers. <i>Cancers</i> , 2021, 13, 4791.	3.7	6
4	Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69. <i>Scientific Reports</i> , 2021, 11, 19151.	3.3	8
5	Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. <i>Pharmaceutics</i> , 2020, 12, 551.	4.5	9
6	Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1972.	4.1	9
7	Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1312.	4.1	7
8	An Affibody Molecule Is Actively Transported into the Cerebrospinal Fluid via Binding to the Transferrin Receptor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2999.	4.1	12
9	Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. <i>Scientific Reports</i> , 2019, 9, 655.	3.3	18
10	Affibody-Mediated Sequestration of Amyloid $\text{A}\beta^2$ Demonstrates Preventive Efficacy in a Transgenic Alzheimer's Disease Mouse Model. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 64.	3.4	16
11	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. <i>Scientific Reports</i> , 2019, 9, 6779.	3.3	8
12	Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of ^{68}Ga -Labeled Tracers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1080.	4.1	21
13	Increase in negative charge of ^{68}Ga /chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. <i>Scientific Reports</i> , 2019, 9, 17710.	3.3	14
14	Autotransporter-Mediated Display of a Na ⁺ -ve Affibody Library on the Outer Membrane of <i>Escherichia coli</i> . <i>Biotechnology Journal</i> , 2019, 14, e1800359.	3.5	9
15	Affibody-mediated imaging of EGFR expression in prostate cancer using radiocobalt-labeled DOTA-ZEGFR:2377. <i>Oncology Reports</i> , 2018, 41, 534-542.	2.6	4
16	Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. <i>Theranostics</i> , 2018, 8, 4462-4476.	10.0	25
17	Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. <i>Cells</i> , 2018, 7, 164.	4.1	19
18	Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab. <i>Molecular Pharmaceutics</i> , 2018, 15, 3394-3403.	4.6	19

#	ARTICLE	IF	CITATIONS
19	In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. <i>Scientific Reports</i> , 2017, 7, 43118.	3.3	20
20	Affibody Molecules in Biotechnological and Medical Applications. <i>Trends in Biotechnology</i> , 2017, 35, 691-712.	9.3	259
21	Identification of proteins that specifically recognize and bind protofibrillar aggregates of amyloid- β . <i>Scientific Reports</i> , 2017, 7, 5949.	3.3	17
22	<i>Staphylococcus carnosus</i> : from starter culture to protein engineering platform. <i>Applied Microbiology and Biotechnology</i> , 2017, 101, 8293-8307.	3.6	36
23	Flow cytometric screening of aggregation inhibitors using a fluorescence-assisted intracellular method. <i>Biotechnology Journal</i> , 2017, 12, 1600364.	3.5	3
24	Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression. <i>International Journal of Oncology</i> , 2017, 51, 1765-1774.	3.3	10
25	P3-050: An Affibody to Monomeric A β as a Novel Therapeutic Approach for Alzheimer's Disease Pathology. , 2016, 12, P835-P836.		1
26	PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. <i>International Journal of Oncology</i> , 2016, 48, 1325-1332.	3.3	50
27	Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. <i>MAbs</i> , 2016, 8, 1195-1209.	5.2	37
28	Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake. <i>EJNMMI Research</i> , 2016, 6, 58.	2.5	13
29	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator. <i>International Journal of Oncology</i> , 2016, 49, 2285-2293.	3.3	27
30	Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 1671-1683.	5.4	18
31	Affibody-mediated PET imaging of HER3 expression in malignant tumours. <i>Scientific Reports</i> , 2015, 5, 15226.	3.3	56
32	A truncated and dimeric format of an Affibody library on bacteria enables FACS-mediated isolation of amyloid- β aggregation inhibitors with subnanomolar affinity. <i>Biotechnology Journal</i> , 2015, 10, 1707-1718.	3.5	35
33	An engineered autotransporter-based surface expression vector enables efficient display of Affibody molecules on OmpT-negative <i>E. coli</i> as well as protease-mediated secretion in OmpT-positive strains. <i>Microbial Cell Factories</i> , 2014, 13, 179.	4.0	19
34	¹⁸⁸ Re-Z _{HER2:V2} , a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1842-1848.	5.0	23
35	Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension. <i>Biotechnology Journal</i> , 2014, 9, 1215-1222.	3.5	46
36	Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re. <i>European Journal of Medicinal Chemistry</i> , 2014, 87, 519-528.	5.5	19

#	ARTICLE	IF	CITATIONS
37	Imaging of HER3-expressing xenografts in mice using a ^{99m} Tc(CO) ₃ -HEHEHE-ZHER3:08699 affibody molecule. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1450-1459.	6.4	40
38	Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity. <i>Scientific Reports</i> , 2014, 4, 7518.	3.3	31
39	Design and evaluation of radiolabeled tracers for tumor imaging. <i>Biotechnology and Applied Biochemistry</i> , 2013, 60, 365-383.	3.1	15
40	Staphylococcal display for combinatorial protein engineering of a head-to-tail affibody dimer binding the Alzheimer amyloid- β peptide. <i>Biotechnology Journal</i> , 2013, 8, 139-145.	3.5	14
41	Affinity proteins and their generation. <i>Journal of Chemical Technology and Biotechnology</i> , 2013, 88, 25-38.	3.2	16
42	Subunit Vaccine Candidates Engineered from the Central Conserved Region of the RSV G Protein Aimed for Parenteral or Mucosal Delivery. , 2013, , 103-118.		1
43	Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification. <i>PLoS ONE</i> , 2013, 8, e62791.	2.5	61
44	HER2-Positive Tumors Imaged Within 1 Hour Using a Site-Specifically ¹¹¹ C-Labeled Sel-Tagged Affibody Molecule. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1446-1453.	5.0	29
45	Generation and Evaluation of Bispecific Affibody Molecules for Simultaneous Targeting of EGFR and HER2. <i>Bioconjugate Chemistry</i> , 2012, 23, 1802-1811.	3.6	26
46	Cellular Effects of HER3-Specific Affibody Molecules. <i>PLoS ONE</i> , 2012, 7, e40023.	2.5	39
47	Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for ^{99m} Tc-labelling at the C terminus. <i>Tumor Biology</i> , 2012, 33, 641-651.	1.8	21
48	Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of ^{99m} Tc-labeled recombinant Affibody molecules. <i>Amino Acids</i> , 2012, 42, 1975-1985.	2.7	16
49	Surface Display on Gram Positive Bacteria. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2012, 4, 171-184.	1.1	25
50	Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand. <i>Protein Expression and Purification</i> , 2011, 76, 127-135.	1.3	32
51	Non-immunoglobulin based protein scaffolds. <i>Current Opinion in Biotechnology</i> , 2011, 22, 843-848.	6.6	128
52	Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. <i>Protein Engineering, Design and Selection</i> , 2011, 24, 385-396.	2.1	62
53	Molecular Design and Optimization of ^{99m} Tc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties. <i>Journal of Nuclear Medicine</i> , 2011, 52, 461-469.	5.0	80
54	Sequestration of the β Peptide Prevents Toxicity and Promotes Degradation In Vivo. <i>PLoS Biology</i> , 2010, 8, e1000334.	5.6	70

#	ARTICLE	IF	CITATIONS
55	Staphylococcal Surface Display in Combinatorial Protein Engineering and Epitope Mapping of Antibodies. <i>Recent Patents on Biotechnology</i> , 2010, 4, 171-182.	0.8	22
56	Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry. <i>Journal of Nuclear Medicine</i> , 2009, 50, 274-283.	5.0	98
57	Engineered affinity proteins—Generation and applications. <i>Journal of Biotechnology</i> , 2009, 140, 254-269.	3.8	103
58	Generation of tumour necrosis factor- α -specific affibody molecules capable of blocking receptor binding <i>in vitro</i> . <i>Biotechnology and Applied Biochemistry</i> , 2009, 54, 93-103.	3.1	33
59	Engineering and characterization of a bispecific HER2—EGFR-binding affibody molecule. <i>Biotechnology and Applied Biochemistry</i> , 2009, 54, 121-131.	3.1	58
60	Engineered affinity proteins for tumour targeting applications. <i>Biotechnology and Applied Biochemistry</i> , 2009, 53, 1-29.	3.1	65
61	Generation of Affibody® ligands binding interleukin-2 receptor β /CD25. <i>Biotechnology and Applied Biochemistry</i> , 2008, 50, 97.	3.1	18
62	Simplified characterization through site-specific protease-mediated release of affinity proteins selected by staphylococcal display. <i>FEMS Microbiology Letters</i> , 2008, 278, 128-136.	1.8	12
63	Epitope mapping of antibodies using bacterial surface display. <i>Nature Methods</i> , 2008, 5, 1039-1045.	19.0	90
64	Directed Evolution to Low Nanomolar Affinity of a Tumor-Targeting Epidermal Growth Factor Receptor-Binding Affibody Molecule. <i>Journal of Molecular Biology</i> , 2008, 376, 1388-1402.	4.2	138
65	Stabilization of a β -hairpin in monomeric Alzheimer's amyloid- β peptide inhibits amyloid formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5099-5104.	7.1	375
66	A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. <i>Protein Engineering, Design and Selection</i> , 2008, 21, 247-255.	2.1	68
67	Evaluation of Staphylococcal Cell Surface Display and Flow Cytometry for Postselectional Characterization of Affinity Proteins in Combinatorial Protein Engineering Applications. <i>Applied and Environmental Microbiology</i> , 2007, 73, 6714-6721.	3.1	40
68	Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. <i>Nuclear Medicine and Biology</i> , 2007, 34, 609-618.	0.6	72
69	Selection and characterization of Affibody ligands binding to Alzheimer amyloid β peptides. <i>Journal of Biotechnology</i> , 2007, 128, 162-183.	3.8	111
70	Affibody-mediated transferrin depletion for proteomics applications. <i>Biotechnology Journal</i> , 2007, 2, 1389-1398.	3.5	42
71	Approaches for systematic proteome exploration. <i>New Biotechnology</i> , 2007, 24, 155-168.	2.7	24
72	Achieving directed immunostimulating complexes incorporation. <i>Expert Review of Vaccines</i> , 2006, 5, 395-403.	4.4	5

#	ARTICLE	IF	CITATIONS
73	Selection and characterization of an HIV-1 gp120-binding affibody ligand. <i>Biotechnology and Applied Biochemistry</i> , 2006, 45, 93.	3.1	26
74	Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 631-638.	6.4	64
75	Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule. <i>Cancer Research</i> , 2006, 66, 4339-4348.	0.9	462
76	Fine affinity discrimination by normalized fluorescence activated cell sorting in staphylococcal surface display. <i>FEMS Microbiology Letters</i> , 2005, 248, 189-198.	1.8	45
77	Applying biotin-streptavidin binding for iscom (immunostimulating complex) association of recombinant immunogens. <i>Biotechnology and Applied Biochemistry</i> , 2005, 41, 163.	3.1	9
78	In Vitro Characterization of a Bivalent Anti-HER-2 Affibody with Potential for Radionuclide-Based Diagnostics. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005, 20, 239-248.	1.0	87
79	General strategies for efficient adjuvant incorporation of recombinant subunit immunogens. <i>Vaccine</i> , 2005, 23, 2331-2335.	3.8	15
80	Biotechnological applications for surface-engineered bacteria. <i>Biotechnology and Applied Biochemistry</i> , 2004, 40, 209.	3.1	90
81	An improved dual-expression concept, generating high-quality antibodies for proteomics research. <i>Biotechnology and Applied Biochemistry</i> , 2003, 38, 231.	3.1	9
82	Fluorescence-Activated Cell Sorting of Specific Affibody-Displaying Staphylococci. <i>Applied and Environmental Microbiology</i> , 2003, 69, 5328-5335.	3.1	17
83	Affinity Proteomics for Systematic Protein Profiling of Chromosome 21 Gene Products in Human Tissues. <i>Molecular and Cellular Proteomics</i> , 2003, 2, 405-414.	3.8	105
84	Engineering of staphylococcal surfaces for biotechnological applications. <i>Journal of Biotechnology</i> , 2002, 96, 67-78.	3.8	20
85	Display of proteins on bacteria. <i>Journal of Biotechnology</i> , 2002, 96, 129-154.	3.8	247
86	A novel affinity gene fusion system allowing protein A-based recovery of non-immunoglobulin gene products. <i>Journal of Biotechnology</i> , 2002, 99, 41-50.	3.8	40
87	Construction and characterization of affibody-Fc chimeras produced in <i>Escherichia coli</i> . <i>Journal of Immunological Methods</i> , 2002, 261, 199-211.	1.4	47
88	General expression vectors for <i>Staphylococcus carnosus</i> enabled efficient production of the outer membrane protein A of <i>Klebsiella pneumoniae</i> . <i>FEMS Microbiology Letters</i> , 2002, 210, 263-270.	1.8	16
89	Vector engineering to improve a staphylococcal surface display system. <i>FEMS Microbiology Letters</i> , 2002, 212, 47-54.	1.8	23
90	Genetic design for facilitated production and recovery of recombinant proteins in <i>Escherichia coli</i> . <i>Biotechnology and Applied Biochemistry</i> , 2002, 35, 91.	3.1	103

#	ARTICLE	IF	CITATIONS
91	Mammalian cell production of a respiratory syncytial virus (RSV) candidate vaccine recovered using a product-specific affinity column. <i>Biotechnology and Applied Biochemistry</i> , 2001, 34, 25.	3.1	8
92	Directed immobilization of recombinant staphylococci on cotton fibers by functional display of a fungal cellulose-binding domain. <i>FEMS Microbiology Letters</i> , 2001, 195, 197-204.	1.8	27
93	In vivo and in vitro lipidation of recombinant immunogens for direct iscom incorporation. <i>Journal of Immunological Methods</i> , 2001, 255, 135-148.	1.4	11
94	Generation of Metal-Binding Staphylococci through Surface Display of Combinatorially Engineered Cellulose-Binding Domains. <i>Applied and Environmental Microbiology</i> , 2001, 67, 4678-4684.	3.1	50
95	Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunisation encoding a secreted RSV G protein-derived antigen. <i>FEMS Immunology and Medical Microbiology</i> , 2000, 29, 247-253.	2.7	28
96	Improved systems for hydrophobic tagging of recombinant immunogens for efficient iscom incorporation. <i>Journal of Immunological Methods</i> , 2000, 238, 181-193.	1.4	24
97	Design and production of recombinant subunit vaccines. <i>Biotechnology and Applied Biochemistry</i> , 2000, 32, 95.	3.1	131
98	Staphylococcal Surface Display of Metal-Binding Polyhistidyl Peptides. <i>Applied and Environmental Microbiology</i> , 2000, 66, 1243-1248.	3.1	121
99	Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides. <i>Vaccine</i> , 2000, 18, 2743-2752.	3.8	47
100	Integrated bioprocess for production of human proinsulin C-peptide via heat release of an intracellular heptameric fusion protein. <i>Journal of Biotechnology</i> , 2000, 76, 215-226.	3.8	15
101	Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunisation encoding a secreted RSV G protein-derived antigen. <i>FEMS Immunology and Medical Microbiology</i> , 2000, 29, 247-253.	2.7	1
102	Engineering of a <i>Staphylococcus carnosus</i> surface display system by substitution or deletion of a <i>Staphylococcus hyicus</i> lipase propeptide. <i>FEMS Microbiology Letters</i> , 1999, 179, 131-139.	1.8	27
103	A surface-displayed cholera toxin B peptide improves antibody responses using food-grade staphylococci for mucosal subunit vaccine delivery. <i>FEMS Immunology and Medical Microbiology</i> , 1999, 25, 289-298.	2.7	26
104	General expression vectors for production of hydrophobically tagged immunogens for direct iscom incorporation. <i>Journal of Immunological Methods</i> , 1999, 222, 171-182.	1.4	14
105	Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. <i>Journal of Biotechnology</i> , 1999, 73, 1-33.	3.8	170
106	The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A protein. <i>Vaccine</i> , 1999, 17, 406-414.	3.8	59
107	Surface display of functional fibronectin-binding domains on <i>Staphylococcus carnosus</i> . <i>FEBS Letters</i> , 1999, 446, 299-304.	2.8	22
108	An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein. <i>Immunotechnology: an International Journal of Immunological Engineering</i> , 1999, 4, 237-252.	2.4	80

#	ARTICLE	IF	CITATIONS
109	[28] Solid-phase differential display and bacterial expression systems in selection and functional analysis of cDNAs. <i>Methods in Enzymology</i> , 1999, 303, 495-511.	1.0	8
110	Engineering of a <i>Staphylococcus carnosus</i> surface display system by substitution or deletion of a <i>Staphylococcus hyicus</i> lipase propeptide. <i>FEMS Microbiology Letters</i> , 1999, 179, 131-139.	1.8	2
111	Staphylococcal Surface Display of Immunoglobulin A (IgA)- and IgE-Specific In Vitro-Selected Binding Proteins (Affibodies) Based on <i>Staphylococcus aureus</i> Protein A. <i>Applied and Environmental Microbiology</i> , 1999, 65, 4134-4140.	3.1	45
112	Differential induction of immunoglobulin G subclasses by immunization with DNA vectors containing or lacking a signal sequence. <i>Immunology Letters</i> , 1998, 61, 201-204.	2.5	57
113	Gene fragment polymerization gives increased yields of recombinant human proinsulin C-peptide. <i>Gene</i> , 1998, 210, 203-210.	2.2	13
114	Chromosomal sequencing using a PCR-based biotin-capture method allowed isolation of the complete gene for the outer membrane protein A of <i>Klebsiella pneumoniae</i> . <i>Gene</i> , 1998, 210, 93-101.	2.2	27
115	Affinity Fusion Strategies for Detection, Purification, and Immobilization of Recombinant Proteins. <i>Protein Expression and Purification</i> , 1997, 11, 1-16.	1.3	302
116	Comparative study of DNA-based immunization vectors: effect of secretion signals on the antibody responses in mice. <i>FEMS Immunology and Medical Microbiology</i> , 1997, 18, 193-202.	2.7	43
117	Binding proteins selected from combinatorial libraries of an α -helical bacterial receptor domain. <i>Nature Biotechnology</i> , 1997, 15, 772-777.	17.5	573
118	The serum albumin-binding region of streptococcal protein G: a bacterial fusion partner with carrier-related properties. <i>Journal of Immunological Methods</i> , 1997, 201, 115-123.	1.4	61
119	Fusions to the cholera toxin B subunit: influence on pentamerization and GM1 binding. <i>Journal of Immunological Methods</i> , 1997, 210, 125-135.	1.4	55
120	Bacterial surface display: trends and progress. <i>Trends in Biotechnology</i> , 1997, 15, 185-192.	9.3	174
121	Induction of Protective Immunity in Rodents by Vaccination with a Prokaryotically Expressed Recombinant Fusion Protein Containing a Respiratory Syncytial Virus G Protein Fragment. <i>Virology</i> , 1997, 230, 155-166.	2.4	131
122	Integrated production of human insulin and its C-peptide. <i>Journal of Biotechnology</i> , 1996, 48, 241-250.	3.8	60
123	Surface display on staphylococci: a comparative study. <i>FEBS Letters</i> , 1996, 390, 327-333.	2.8	32
124	Upstream Strategies to Minimize Proteolytic Degradation upon Recombinant Production in <i>Escherichia coli</i> . <i>Protein Expression and Purification</i> , 1996, 7, 129-136.	1.3	91
125	A General Bacterial Expression System for Functional Analysis of cDNA-Encoded Proteins. <i>Protein Expression and Purification</i> , 1996, 7, 447-457.	1.3	36
126	A Novel Expression System for <i>Salmonella typhimurium</i> Allowing High Production Levels, Product Secretion and Efficient Recovery. <i>Biochemical and Biophysical Research Communications</i> , 1996, 218, 356-359.	2.1	10

#	ARTICLE	IF	CITATIONS
127	Multiple affinity domains for the detection, purification and immobilization of recombinant proteins. , 1996, 9, 585-594.		57
128	Surface display compared to periplasmic expression of a malarial antigen in <i>Salmonella typhimurium</i> and its implications for immunogenicity. FEMS Immunology and Medical Microbiology, 1995, 12, 175-185.	2.7	42
129	Immunogens containing sequences from antigen Pf332 induce <i>Plasmodium falciparum</i> reactive antibodies which inhibit parasite growth but not cytoadherence. Parasite Immunology, 1995, 17, 341-352.	1.5	23
130	Hydrophobicity engineering to facilitate surface display of heterologous gene products on <i>Staphylococcus xylosus</i> . Journal of Biotechnology, 1995, 42, 207-219.	3.8	47
131	Hydrophobicity Engineering to Increase Solubility and Stability of a Recombinant Protein from Respiratory Syncytial Virus. FEBS Journal, 1995, 230, 38-44.	0.2	58
132	Single-Step Recovery of a Secreted Recombinant Protein by Expanded Bed Adsorption. Bio/technology, 1994, 12, 285-288.	1.5	129
133	Engineered bacterial receptors in immunology. Current Opinion in Immunology, 1993, 5, 272-277.	5.5	29
134	Cell-surface display of heterologous epitopes on <i>Staphylococcus xylosus</i> as a potential delivery system for oral vaccination. Gene, 1993, 128, 89-94.	2.2	80
135	Semi-automated solid-phase DNA sequencing. Trends in Biotechnology, 1992, 10, 52-55.	9.3	12
136	Solid phase in vitro mutagenesis using plasmid DNA template. Nucleic Acids Research, 1990, 18, 5107-5112.	14.5	34
137	A general strategy for polymerization, assembly and expression of epitope-carrying peptides applied to the <i>Plasmodium falciparum</i> antigen Pf155/RESA. Gene, 1990, 89, 187-193.	2.2	31
138	A dual expression system for the generation, analysis and purification of antibodies to a repeated sequence of the <i>Plasmodium falciparum</i> antigen Pf155/RESA. Journal of Immunological Methods, 1989, 124, 43-52.	1.4	81
139	Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. Nucleic Acids Research, 1989, 17, 4937-4946.	14.5	809
140	Solid phase DNA sequencing using the biotin-avidin system. Nucleic Acids Research, 1988, 16, 3025-3038.	14.5	66